No significant discrepancies were seen
At the one and two year marks, the researchers did not see any significant discrepancies between the results of the two groups for patients who had HbA1c of 7% or less. In fact, the mean change from baseline to two years was .2% for those on the repaglinide and -.2% for those on insulin.
There were also no significant advantages or disadvantages between the two groups when it came to pulmonary function or mean blood glucose concentration at the one and two year marks.
A -0.7 change in the BMI z score was found in the two groups at one year, but at two years those results were no longer present.